Analysts Anticipate HTG Molecular Diagnostics Inc (HTGM) Will Post Earnings of -$0.19 Per Share
Equities analysts expect that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will report earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for HTG Molecular Diagnostics’ earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.18). HTG Molecular Diagnostics reported earnings per share of ($0.46) during the same quarter last year, which would indicate a positive year-over-year growth rate of 58.7%. The company is expected to announce its next earnings report on Tuesday, November 6th.
On average, analysts expect that HTG Molecular Diagnostics will report full year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.79) to ($0.63). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.57) to ($0.45). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover HTG Molecular Diagnostics.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Thursday, August 9th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%. The company had revenue of $4.91 million for the quarter, compared to analyst estimates of $5.30 million.
NASDAQ:HTGM traded down $0.12 during mid-day trading on Tuesday, hitting $3.54. 534,117 shares of the company’s stock traded hands, compared to its average volume of 747,873. HTG Molecular Diagnostics has a twelve month low of $1.71 and a twelve month high of $5.83. The company has a quick ratio of 9.29, a current ratio of 9.50 and a debt-to-equity ratio of 0.35.
Institutional investors have recently bought and sold shares of the company. New York State Common Retirement Fund purchased a new stake in shares of HTG Molecular Diagnostics in the 1st quarter valued at about $170,000. Northern Trust Corp acquired a new position in HTG Molecular Diagnostics in the 1st quarter valued at about $189,000. BlackRock Inc. increased its position in HTG Molecular Diagnostics by 322.8% in the 2nd quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock valued at $238,000 after acquiring an additional 55,769 shares during the period. Stifel Financial Corp acquired a new position in HTG Molecular Diagnostics in the 1st quarter valued at about $343,000. Finally, Acadian Asset Management LLC acquired a new position in HTG Molecular Diagnostics in the 2nd quarter valued at about $353,000. 49.17% of the stock is owned by institutional investors and hedge funds.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Read More: How to Use a Moving Average for Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.